Recently, a well-known ecological platform in the field of biopharmaceutical innovation in China has reached a strategic cooperation agreement with Yiyi and the globally leading professional service agency EY. The two sides will start from the first China National New Drug Conference (CPIC 2026) to be held at the National Convention and Exhibition Center (Shanghai) from July 22-24, 2026, and engage in in-depth cooperation on core issues such as global cooperation among Chinese innovative pharmaceutical companies, AI transformation of the biopharmaceutical industry, and capital market empowerment, jointly promoting the integration of China's pharmaceutical innovation forces into the global industrial landscape.

The 1st China Pharmaceutical Innovation Conference will be held at the National Convention and Exhibition Center (Shanghai) from July 22-24, 2026. The conference, benchmarked against J.P. Morgan, gathers multinational pharmaceutical companies, international investment banks, top investment institutions, and over a thousand innovative enterprises to build a new paradigm of "China Innovation Global Cooperation Shanghai Trading". It is the most influential global industry event in the field of innovative drugs in China.

Scan the code to register immediately
Early bird tickets are available for a limited time at a 25% discount!!

What will both parties do?

At the CPIC 2026 conference, EY will be deeply involved in planning multiple themed special sessions, focusing on the following core topics for contribution reports or dialogue sharing:

Cross border transaction architecture and tax optimization
AI driven drug development and regulatory technology
Innovative pharmaceutical company IPO, NewCo model, and USD fund layout
Design of Global Regulatory Compliance Framework

At the same time, both parties will jointly release an in-depth industry research report to analyze the path of Chinese pharmaceutical companies going global from a global perspective. Ernst&Young's global biopharmaceutical industry clients and partners will be invited to attend and precisely connect with the Chinese innovation ecosystem through the Tongyi platform.

Message from both parties
 

Dr. Cheng Zengjiang, founder and chairman of Tongyi, said:
Chinese innovative drugs are moving from 'following' to 'leading', but the last mile of globalization requires the protection of professional capabilities. Ernst&Young's global expertise in cross-border transactions, capital markets, and ESG will provide critical infrastructure for Chinese pharmaceutical companies' overseas expansion. This is not a sponsorship of a conference, but an ecological level strategic co construction.

Bi Shunjie, the business manager and partner of Anyong Greater China, said:
EY has been rooted in Greater China for over 50 years and deeply understands the global demands of Chinese pharmaceutical companies. As a highly influential industry ecosystem platform in the field of innovative medicine in China, Tongyi has gathered cutting-edge wisdom and resources in the industry. We look forward to taking CPIC, an international event, as an opportunity to fully leverage EY's global network and professional insights, accurately connect with industry needs, and provide practical and in-depth professional empowerment for Chinese innovative pharmaceutical companies' high-quality overseas expansion and global layout.

Wu Xiaoying, Partner in Chief of Consulting Services at Anyong Greater China and Co Head of Life Sciences Industry in Greater China, stated:
We are honored to join hands with Tong Xieyi and participate deeply in the CPIC conference together. The globalization journey of Chinese pharmaceutical enterprises not only requires the assistance of cross-border transactions and capital, but also the comprehensive protection of top-level strategy, management structure, compliance operation, and digital transformation. EY will fully devote industry resources to support the internationalization of local pharmaceutical companies with end-to-end professional consulting capabilities. We look forward to building an open, empowering, and mutually beneficial ecosystem for life science innovation through this strategic joint construction with Tong Xieyi.

Fei Fan, the Chief Partner of Audit Services at Anyonghua Central District and Co Head of Life Science Industry in Greater China, stated:
In the current era where capital in the pharmaceutical industry is returning to rationality and the valuation system is being reshaped, companies need to look inward and cultivate their internal strength. EY has been deeply involved in the field of life sciences for many years and has always worked alongside Chinese innovative pharmaceutical companies to tackle cyclical challenges. We look forward to leveraging CPIC as an international platform to transform EY's professional experience in compliance governance, capital operations, and global layout into a solid force to safeguard the steady progress of Chinese innovative pharmaceutical companies.

About EY

Ernst&Young is one of the world's leading professional service providers for auditing, consulting, taxation, strategy, and transactions, employing over 400000 personnel in more than 150 countries and regions.
EY's member institutions in Greater China are owned and managed by local partners. In the professional service fields of auditing, consulting, strategy, taxation, and transactions, the EY team addresses the most complex and urgent challenges by proposing better questions and discovering innovative solutions.
In 1968, Ernst&Young began writing a brilliant epic in Greater China for over half a century. For over half a century, Ernst&Young has provided excellent and comprehensive professional services to clients, becoming a trusted strategic partner and consulting advisor for many clients in Greater China. EY has achieved today's success with first-class talent, innovative spirit, adherence to social responsibility, leading high-quality sustainable development.
An Yong Greater China region has 24000 professionals, including over 1000 partners. In the future, we will continue to leverage our professional advantages, build a mutually beneficial ecosystem, establish trust in the capital market, and actively promote sustainable development in the Greater China region.